Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more
Esperion Therapeutics Inc (ESPR) - Net Assets
Latest net assets as of September 2025: $-451.36 Million USD
Based on the latest financial reports, Esperion Therapeutics Inc (ESPR) has net assets worth $-451.36 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($364.02 Million) and total liabilities ($815.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-451.36 Million |
| % of Total Assets | -123.99% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -235.32% |
| Growth Volatility | 704.72 |
Esperion Therapeutics Inc - Net Assets Trend (1999–2024)
This chart illustrates how Esperion Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Esperion Therapeutics Inc (1999–2024)
The table below shows the annual net assets of Esperion Therapeutics Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-388.72 Million | +14.57% |
| 2023-12-31 | $-454.99 Million | -40.53% |
| 2022-12-31 | $-323.78 Million | -64.40% |
| 2021-12-31 | $-196.94 Million | -104.86% |
| 2020-12-31 | $-96.13 Million | -581.87% |
| 2019-12-31 | $19.95 Million | -74.78% |
| 2018-12-31 | $79.12 Million | -67.67% |
| 2017-12-31 | $244.69 Million | +7.04% |
| 2016-12-31 | $228.60 Million | -20.42% |
| 2015-12-31 | $287.26 Million | +115.09% |
| 2014-12-31 | $133.55 Million | +80.26% |
| 2013-12-31 | $74.09 Million | +526.06% |
| 2012-12-31 | $-17.39 Million | -187.11% |
| 2011-12-31 | $-6.06 Million | -115.63% |
| 2002-12-31 | $38.74 Million | -41.74% |
| 2001-12-31 | $66.50 Million | -1.76% |
| 2000-12-31 | $67.69 Million | +2304.91% |
| 1999-12-31 | $2.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Esperion Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 158821575300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $196.00K | % |
| Other Components | $1.21 Billion | % |
| Total Equity | $-388.72 Million | 100.00% |
Esperion Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Esperion Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pfeiffer Vacuum Technology AG
PINK:PFFVF
|
$604.24 Million |
|
Guangdong Jinma Entertainment Corp Ltd
SHE:300756
|
$604.28 Million |
|
ULS Group Inc
OTCGREY:ULPRF
|
$604.34 Million |
|
ViTrox Corporation Bhd
KLSE:0097
|
$604.35 Million |
|
GuangZhou BaiYun Elec Equip Co
SHG:603861
|
$604.09 Million |
|
YiDong Electronics Technology Co. Ltd.
SHE:301123
|
$604.01 Million |
|
NORVA24 GROUP AB (PUBL.)
F:WG0
|
$603.67 Million |
|
Silicon Integrated Systems Corp
TW:2363
|
$603.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Esperion Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -454,994,000 to -388,722,000, a change of 66,272,000.
- Net loss of 51,745,000 reduced equity.
- New share issuances of 91,185,000 increased equity.
- Other factors increased equity by 26,832,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-51.74 Million | -13.31% |
| Share Issuances | $91.19 Million | +23.46% |
| Other Changes | $26.83 Million | +6.9% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Esperion Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $2.09 | $2.71 | x |
| 2000-12-31 | $22.95 | $2.71 | x |
| 2001-12-31 | $17.01 | $2.71 | x |
| 2002-12-31 | $9.25 | $2.71 | x |
| 2011-12-31 | $-0.63 | $2.71 | x |
| 2012-12-31 | $-1.81 | $2.71 | x |
| 2013-12-31 | $4.83 | $2.71 | x |
| 2014-12-31 | $8.16 | $2.71 | x |
| 2015-12-31 | $13.05 | $2.71 | x |
| 2016-12-31 | $10.14 | $2.71 | x |
| 2017-12-31 | $10.22 | $2.71 | x |
| 2018-12-31 | $-22.36 | $2.71 | x |
| 2019-12-31 | $0.74 | $2.71 | x |
| 2020-12-31 | $-3.50 | $2.71 | x |
| 2021-12-31 | $-6.81 | $2.71 | x |
| 2022-12-31 | $-4.88 | $2.71 | x |
| 2023-12-31 | $-4.41 | $2.71 | x |
| 2024-12-31 | $-2.08 | $2.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Esperion Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.57%
- • Asset Turnover: 0.97x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-66.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -379.09% | 0.00% | 0.00x | 2.84x | $-10.95 Million |
| 2000 | -40.74% | -1378800.00% | 0.00x | 1.15x | $-34.35 Million |
| 2001 | -37.49% | 0.00% | 0.00x | 1.18x | $-31.58 Million |
| 2002 | -74.15% | 0.00% | 0.00x | 1.33x | $-32.60 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.21 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.00 Million |
| 2013 | -35.21% | -0.52% | 63.57x | 1.06x | $-33.50 Million |
| 2014 | -27.24% | 0.00% | 0.00x | 1.07x | $-49.73 Million |
| 2015 | -17.33% | 0.00% | 0.00x | 1.03x | $-78.51 Million |
| 2016 | -32.80% | 0.00% | 0.00x | 1.07x | $-97.84 Million |
| 2017 | -68.24% | 0.00% | 0.00x | 1.14x | $-191.46 Million |
| 2018 | 0.00% | -109.40% | 1.29x | 0.00x | $-142.00 Million |
| 2019 | -487.04% | -65.49% | 0.69x | 10.75x | $-99.16 Million |
| 2020 | 0.00% | -63.09% | 0.64x | 0.00x | $-133.94 Million |
| 2021 | 0.00% | -343.04% | 0.21x | 0.00x | $-249.41 Million |
| 2022 | 0.00% | -309.58% | 0.30x | 0.00x | $-201.28 Million |
| 2023 | 0.00% | -179.87% | 0.57x | 0.00x | $-163.75 Million |
| 2024 | 0.00% | -15.57% | 0.97x | 0.00x | $-12.87 Million |
Industry Comparison
This section compares Esperion Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Esperion Therapeutics Inc (ESPR) | $-451.36 Million | -379.09% | N/A | $604.15 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |